Avoro Capital Advisors LLC Has $77.68 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Avoro Capital Advisors LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 12,570,000 shares of the biotechnology company’s stock after selling 480,000 shares during the period. BioCryst Pharmaceuticals comprises 1.0% of Avoro Capital Advisors LLC’s holdings, making the stock its 24th biggest position. Avoro Capital Advisors LLC owned approximately 0.06% of BioCryst Pharmaceuticals worth $77,683,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of BCRX. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock worth $106,405,000 after purchasing an additional 2,371,401 shares during the period. Norges Bank bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth $13,278,000. Rafferty Asset Management LLC raised its holdings in BioCryst Pharmaceuticals by 18.3% in the 4th quarter. Rafferty Asset Management LLC now owns 955,587 shares of the biotechnology company’s stock valued at $5,724,000 after acquiring an additional 147,699 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 4,041 shares during the period. Finally, Braidwell LP grew its holdings in shares of BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock worth $34,254,000 after purchasing an additional 355,497 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

BCRX has been the subject of several recent analyst reports. JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.11 on Monday. The company’s 50 day moving average price is $7.79 and its two-hundred day moving average price is $6.36. The firm has a market capitalization of $1.67 billion, a P/E ratio of -7.58 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to analyst estimates of $98.30 million. During the same period last year, the business earned ($0.24) EPS. The company’s revenue was up 34.9% compared to the same quarter last year. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.45 earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.